Literature DB >> 24911477

First PDE4 inhibitor for psoriasis hits the market but impact is uncertain.

Mark Ratner.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24911477     DOI: 10.1038/nbt0614-505

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  3 in total

1.  IL-17-targeting biologics aim to become standard of care in psoriasis.

Authors:  Mark Ratner
Journal:  Nat Biotechnol       Date:  2015-01       Impact factor: 54.908

2.  Celgene shells out for antisense drug.

Authors:  Mark Ratner
Journal:  Nat Biotechnol       Date:  2014-07       Impact factor: 54.908

Review 3.  Targeted Treatment for Erythrodermic Psoriasis: Rationale and Recent Advances.

Authors:  Shuai Shao; Gang Wang; Emanual Maverakis; Johann E Gudjonsson
Journal:  Drugs       Date:  2020-04       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.